Century Therapeutics said its cash, cash equivalents and marketable securities rose to $217.0 million at March 31, 2026, up from $117.1 million at December 31, 2025, after it completed an oversubscribed $135 million private placement in January.
The company said that balance should fund operations into the first quarter of 2029. In the first quarter, net cash used in operations fell to $25.3 million from $34.6 million a year earlier.
Research and development spending dropped to $17.1 million from $26.6 million in the same quarter of 2025, a decline of $9.5 million. General and administrative expense also fell, to $6.6 million from $8.4 million.
Century reported a net loss of $21.6 million for the quarter, compared with net income of $76.6 million in the first quarter of 2025.
On the pipeline side, the company said CNTY-813, its type 1 diabetes islet therapy, remains on track for an IND filing in the fourth quarter of 2026, with initial clinical data expected in the second half of 2027. Century also said it plans an oral presentation on the program at the ADA annual scientific sessions on June 8, 2026.
For CNTY-308, the company said it remains on track to complete IND-enabling work and initiate clinical testing in 2026. As a result of these announcements, the company's shares have moved 0.0% on the market, and are now trading at a price of $2.29. Check out the company's full 8-K submission here.
